Wanbury Ltd (WANBURY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 965190,
    "name": "Wanbury",
    "stock_name": "Wanbury",
    "full_name": "Wanbury Ltd",
    "name_url": "stocks-analysis/wanbury",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "247.20",
    "chg": 31,
    "chgp": "14.34%",
    "dir": 1,
    "prev_price": "216.20",
    "mcapval": "779.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524212,
    "symbol": "WANBURY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE107F01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "11.49 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/wanbury-965190-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Wanbury Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wanbury-shares-slip-as-technical-indicators-signal-bearish-momentum-3745501",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Wanbury_technicaldot_3745501.png",
        "date": "2025-12-04 08:11:16",
        "description": "Wanbury, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and neutral signals across multiple timeframes. Recent market data reveals a downward price movement accompanied by mixed technical indicator readings, suggesting a cautious outlook for investors analysing the stock’s near-term trajectory."
      },
      {
        "title": "Why is Wanbury falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-wanbury-fallingrising-3745032",
        "imagepath": "",
        "date": "2025-12-04 00:55:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Relative Performance</strong></p>\n<p>Despite Wanbury’s impressive long-term returns, with gains of 381.94% over three years and 568.84% over five years, the stock has struggled in recent months. Over the past month, Wanbury’s share price has declined by 8.37%, contrasting with the Sensex’s 1.34% gain during the same period. Year-to-date, the stock is down 16.35%, while the broader market has risen 8.92%. This divergence highlights Wanbury’s recent underperformance against the benchmark, which may be contributing to investor caution.</p>\n<p>On the day in question, Wanbury underperformed its sector by 2.92%, signalling weakness relative to peers. The stock’s price touched an intraday low of ₹236.15, representing a 5.07% drop from the previous close, and the weight..."
      },
      {
        "title": "Wanbury’s Evaluation Revised Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/wanbury-downgraded-to-sell-by-marketsmojo-amid-mixed-financial-signals-3737071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Wanbury_mojoScore_3737071.png",
        "date": "2025-11-30 10:24:53",
        "description": "Wanbury, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial trends, valuation appeal, and technical indicators. This shift highlights the nuanced challenges and opportunities facing the company amid sector dynamics and investor sentiment."
      },
      {
        "title": "Wanbury Stock Analysis: Technical Momentum Shifts Amid Mixed Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wanbury-shares-show-mixed-technical-signals-amid-price-momentum-shift-3734715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Wanbury_technicaldot_3734715.png",
        "date": "2025-11-28 08:06:59",
        "description": "Wanbury, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators suggest a nuanced market assessment, with mixed signals emerging from key metrics such as MACD, RSI, and moving averages."
      },
      {
        "title": "How has been the historical performance of Wanbury?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-wanbury-3703755",
        "imagepath": "",
        "date": "2025-11-15 00:12:13",
        "description": "Answer:\nThe historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health.\n\nBreakdown:\nWanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sh..."
      },
      {
        "title": "How has been the historical performance of Wanbury?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-wanbury-3699514",
        "imagepath": "",
        "date": "2025-11-13 23:39:39",
        "description": "Answer:\nThe historical performance of Wanbury shows a fluctuating trend in net sales, with a notable increase from INR 575.65 crore in March 2024 to INR 599.51 crore in March 2025. This follows a dip in sales to INR 499.65 crore in March 2023, after which the company had a slight recovery in March 2024. The total operating income mirrored this trend, reaching INR 599.51 crore in March 2025. Operating profit, excluding other income, improved to INR 76.31 crore in March 2025 from INR 70.00 crore in March 2024, indicating a strengthening operational performance. However, profit before tax declined to INR 29.55 crore in March 2025 from INR 56.34 crore in March 2024, reflecting increased interest expenses which rose to INR 36.95 crore. The profit after tax also decreased to INR 30.53 crore in March 2025 from INR 55.96 crore in March 2024. \n\nIn terms of assets and liabilities, total assets increased to INR 406.88..."
      },
      {
        "title": "Wanbury Faces Bearish Technical Trends Amidst Market Volatility and Historical Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wanburys-technical-trend-shifts-from-sideways-to-bearish-amid-stock-volatility-3696597",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Wanbury_technicaldot_3696597.png",
        "date": "2025-11-13 08:09:29",
        "description": "Wanbury, a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly amid significant volatility over the past year. Despite recent underperformance compared to the Sensex, the company has demonstrated impressive long-term growth, with substantial returns over three and five years."
      },
      {
        "title": "How has been the historical performance of Wanbury?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-wanbury-3694187",
        "imagepath": "",
        "date": "2025-11-12 23:23:36",
        "description": "Answer:\nThe historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years.\n\nBreakdown:\nWanbury's net sales have increased from 367.45 Cr in Mar'20 to 599.51 Cr in Mar'25, indicating a steady growth trajectory. The total operating income followed a similar pattern, rising from 391.37 Cr in Mar'19 to 599.51 Cr in Mar'25. However, the company's operating profit (PBDIT) has shown volatility, peaking at 79.80 Cr in Mar'25 after a low of 15.54 Cr in Mar'19. Profit before tax has also fluctuated significantly, with a high of 81.13 Cr in Mar'22 and a low of -10.29 Cr in Mar'23, ultimately landing at 29.55 Cr in Mar'25. The profit after tax mirrored this trend, moving from a loss of 24.85 Cr in Mar'19 to a profit of 30.53 Cr in Mar'25. Wanbury's total liabilities increased from 275.33 Cr in Mar'20 to 406.88 Cr in Mar'25, while total assets also rose from 275.33 Cr in Mar'20 to 4..."
      },
      {
        "title": "Wanbury Ltd Forms Death Cross, Signaling Potential Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wanbury-ltd-forms-death-cross-signaling-potential-bearish-trend-ahead-3693095",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Wanbury_dealthcross_3693095.png",
        "date": "2025-11-12 18:00:50",
        "description": "Wanbury Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, has recently encountered a Death Cross, signaling potential bearish momentum. With a market cap of Rs 843.00 crore and a P/E ratio significantly below the industry average, the stock has underperformed over the past year, raising caution among investors."
      }
    ],
    "total": 961,
    "sid": "965190",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/wanbury-965190"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "28-Jan-2026",
      "details": "Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve Intimation of Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "28-Jan-2026",
      "details": "Wanbury Launches Commercial production of key anaesthetic API at Tanuku Facility.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Certificate under reg. 74 (5) of SEBI (DP) Reg 2018",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Wanbury Ltd has declared <strong>10%</strong> dividend, ex-date: 29 Jul 10",
          "dt": "2010-07-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Wanbury Technical Momentum Shifts Amid Mixed Market Signals

2025-12-04 08:11:16

Wanbury, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and neutral signals across multiple timeframes. Recent market data reveals a downward price movement accompanied by mixed technical indicator readings, suggesting a cautious outlook for investors analysing the stock’s near-term trajectory.

Why is Wanbury falling/rising?

2025-12-04 00:55:51

Short-Term Price Movement and Relative Performance Despite Wanbury’s impressive long-term returns, with gains of 381.94% over three years and 568.84% over five years, the stock has struggled in recent months. Over the past month, Wanbury’s share price has declined by 8.37%, contrasting with the Sensex’s 1.34% gain during the same period. Year-to-date, the stock is down 16.35%, while the broader market has risen 8.92%. This divergence highlights Wanbury’s recent underperformance against the benchmark, which may be contributing to investor caution. On the day in question, Wanbury underperformed its sector by 2.92%, signalling weakness relative to peers. The stock’s price touched an intraday low of ₹236.15, representing a 5.07% drop from the previous close, and the weight...

Wanbury’s Evaluation Revised Amid Mixed Financial and Technical Signals

2025-11-30 10:24:53

Wanbury, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial trends, valuation appeal, and technical indicators. This shift highlights the nuanced challenges and opportunities facing the company amid sector dynamics and investor sentiment.

Wanbury Stock Analysis: Technical Momentum Shifts Amid Mixed Indicators

2025-11-28 08:06:59

Wanbury, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators suggest a nuanced market assessment, with mixed signals emerging from key metrics such as MACD, RSI, and moving averages.

How has been the historical performance of Wanbury?

2025-11-15 00:12:13

Answer: The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years, with notable changes in net sales, profits, and overall financial health. Breakdown: Wanbury's net sales increased from 499.65 Cr in Mar'23 to 599.51 Cr in Mar'25, reflecting a positive growth trajectory. Total operating income followed a similar pattern, rising to 599.51 Cr in Mar'25 from 499.65 Cr in Mar'23. However, the company faced challenges with profitability, as operating profit (PBDIT) rose to 79.80 Cr in Mar'25 from 24.08 Cr in Mar'23, but profit before tax dropped to 29.55 Cr in Mar'25 from 56.34 Cr in Mar'24. Profit after tax also decreased to 30.53 Cr in Mar'25 from 55.96 Cr in Mar'24. The company's total liabilities increased to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, while total assets also rose to 406.88 Cr in Mar'25 from 337.62 Cr in Mar'24, indicating a growing balance sh...

How has been the historical performance of Wanbury?

2025-11-13 23:39:39

Answer: The historical performance of Wanbury shows a fluctuating trend in net sales, with a notable increase from INR 575.65 crore in March 2024 to INR 599.51 crore in March 2025. This follows a dip in sales to INR 499.65 crore in March 2023, after which the company had a slight recovery in March 2024. The total operating income mirrored this trend, reaching INR 599.51 crore in March 2025. Operating profit, excluding other income, improved to INR 76.31 crore in March 2025 from INR 70.00 crore in March 2024, indicating a strengthening operational performance. However, profit before tax declined to INR 29.55 crore in March 2025 from INR 56.34 crore in March 2024, reflecting increased interest expenses which rose to INR 36.95 crore. The profit after tax also decreased to INR 30.53 crore in March 2025 from INR 55.96 crore in March 2024. In terms of assets and liabilities, total assets increased to INR 406.88...

Wanbury Faces Bearish Technical Trends Amidst Market Volatility and Historical Growth

2025-11-13 08:09:29

Wanbury, a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly amid significant volatility over the past year. Despite recent underperformance compared to the Sensex, the company has demonstrated impressive long-term growth, with substantial returns over three and five years.

How has been the historical performance of Wanbury?

2025-11-12 23:23:36

Answer: The historical performance of Wanbury shows a fluctuating trend in key financial metrics over the years. Breakdown: Wanbury's net sales have increased from 367.45 Cr in Mar'20 to 599.51 Cr in Mar'25, indicating a steady growth trajectory. The total operating income followed a similar pattern, rising from 391.37 Cr in Mar'19 to 599.51 Cr in Mar'25. However, the company's operating profit (PBDIT) has shown volatility, peaking at 79.80 Cr in Mar'25 after a low of 15.54 Cr in Mar'19. Profit before tax has also fluctuated significantly, with a high of 81.13 Cr in Mar'22 and a low of -10.29 Cr in Mar'23, ultimately landing at 29.55 Cr in Mar'25. The profit after tax mirrored this trend, moving from a loss of 24.85 Cr in Mar'19 to a profit of 30.53 Cr in Mar'25. Wanbury's total liabilities increased from 275.33 Cr in Mar'20 to 406.88 Cr in Mar'25, while total assets also rose from 275.33 Cr in Mar'20 to 4...

Wanbury Ltd Forms Death Cross, Signaling Potential Bearish Trend Ahead

2025-11-12 18:00:50

Wanbury Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, has recently encountered a Death Cross, signaling potential bearish momentum. With a market cap of Rs 843.00 crore and a P/E ratio significantly below the industry average, the stock has underperformed over the past year, raising caution among investors.

View All News